Non-24-hour Sleep-wake Disorder
📧 Sign up to get email alerts when something new happens for Non-24-hour Sleep-wake Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Improving Sleep in Visually Impaired Patients [NA]
A clinical trial is evaluating Electrical Vestibular Nerve Stimulation (VeNS) to improve sleep in visually impaired individuals, with recrui…
-
CLINICAL_TRIALS trial_result · 2025-08-03Clinical Trial Update: Breath Biomarkers for Sleep Loss and Circadian Timing
A terminated Brigham and Women's Hospital clinical trial investigated breath biomarkers for sleep loss and circadian timing in shift-work an…
-
CLINICAL_TRIALS trial_result · 2024-04-03Clinical Trial Update: Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception [Phase 3]
Phase 3 safety trial update for tasimelteon in blind individuals with no light perception and non-24-hour sleep-wake disorder; status indica…
-
FDA approval · 2023-01-12FDA Approved: TASIMELTEON — Original Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal Pharmaceuticals NY LLC's generic tasimelteon through an original application, enabling a generic version to be marke…
-
FDA approval · 2022-12-20FDA Approved: TASIMELTEON — Original Application (Apotex Corp.)
The FDA approved Apotex Corp.'s original ANDA for tasimelteon, establishing a generic version of the sleep-wake disorder medication. Tasimel…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-12-01FDA Approved: HETLIOZ LQ — Original Application (Vanda Pharmaceuticals Inc.)
FDA approval of Hetlioz LQ (tasimelteon) under the original NDA submitted by Vanda Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2016-07-22Clinical Trial Update: Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™) [Phase 4]
Open-label Phase 4 study assessing the absolute bioavailability of tasimelteon (HETLIOZ) in adults with non-24-hour sleep-wake disorder; res…
-
CLINICAL_TRIALS trial_result · 2015-04-21Clinical Trial Update: Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception [Phase 3]
Phase 3 clinical trial of tasimelteon for Non-24-Hour Sleep-Wake Disorder in blind individuals with no light perception has completed.
-
FDA approval · 2014-12-12FDA Approved: HETLIOZ — Supplemental Application (Vanda Pharmaceuticals Inc.)
FDA approved a supplemental application for HETLIOZ (tasimelteon) by Vanda Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2014-10-16Clinical Trial Update: Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder [Phase 3]
Phase 3 trial evaluating the efficacy and safety of tasimelteon versus placebo in totally blind individuals with Non-24-Hour Sleep-Wake Diso…
-
CLINICAL_TRIALS trial_result · 2014-10-10Clinical Trial Update: Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder [Phase 3]
A Phase 3 withdrawal study evaluating the maintenance effect of tasimelteon for Non-24-Hour Sleep-Wake Disorder; the study is completed with…
-
FDA approval · 2014-01-31FDA Approved: HETLIOZ — Original Application (Vanda Pharmaceuticals Inc.)
The FDA granted original approval for Hetlioz (tasimelteon) from Vanda Pharmaceuticals for non-24-hour sleep-wake disorder, a circadian rhyt…
-
CLINICAL_TRIALS trial_result · 2009-09-09Clinical Trial Update: Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects [Phase 2]
Phase 2 trial updates show Circadin (melatonin) demonstrating efficacy and safety for Non-24-hour sleep-wake disorder in totally blind subje…